ValuEngine cut shares of Antriabio, Inc. (OTCMKTS:ANTB) from a sell rating to a strong sell rating in a research note published on Tuesday.

Antriabio (ANTB) opened at 1.00 on Tuesday. Antriabio has a 1-year low of $0.62 and a 1-year high of $1.49. The firm has a 50-day moving average of $1.10 and a 200-day moving average of $1.11. The firm’s market capitalization is $53.73 million.

COPYRIGHT VIOLATION WARNING: “ValuEngine Lowers Antriabio, Inc. (ANTB) to Strong Sell” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at

About Antriabio

AntriaBio, Inc is a biopharmaceutical company. The Company develops sustained release injectable therapies. The Company’s products include AB101 and AB301. The Company’s lead product candidate, AB101, is a microsphere formulation of PEGylated human recombinant insulin, is being developed as an extended acting basal insulin intended for once-weekly subcutaneous injection, for use alone and in combination with bolus prandial insulin or oral glucose lowering therapies, to improve glycemic control in patients with Type 1 and Type 2 Diabetes Mellitus.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Antriabio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antriabio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.